Novartis, not to be outdone by respiratory rivals, inks ‘smart inhaler’ deal

Carly Helfand Respiratory drugmakers have been looking to "smart inhaler" technology to give them a leg up on marketing in a crowded field. And Novartis wants a part ...

GlaxoSmithKline bags an FDA OK for its asthma drug with eyes on a respiratory turnaround

Damian Garde GlaxoSmithKline won FDA approval for an antibody designed to treat severe asthma, leading a pack of drugmakers at work on similar therapies as it seeks to bolster its respiratory ...

Boehringer gets respiratory boost with batch of Spiolto nods in EU

Carly Helfand When Boehringer Ingelheim's COPD drug Stiolto Respimat won U.S. approval early last month, the company's head of pharma marketing and sales, Allan Hillgrove, acknowledged ...

AstraZeneca continues its respiratory land grab with $600M-plus Actavis deal

Carly Helfand AstraZeneca CEO Pascal Soriot has said he wants to dominate in the respiratory field. Actavis CEO Brent Saunders has no such ambitions. Now, the two have struck a deal. FiercePharma ...

GlaxoSmithKline heads to the FDA with its next big respiratory bet

Damian Garde GlaxoSmithKline is racing to be the first on the market with a new approach to treating severe asthma, filing U.S. and European applications for the injectable mepolizumab ...

Almirall sends 719 employees to AstraZeneca as part of respiratory deal

Emily Wasserman AstraZeneca signed on the dotted line for Almirall, gaining access to the company's promising respiratory drug portfolio and products currently under development. ...

AstraZeneca seals the deal for Almirall’s respiratory meds

Emily Wasserman With generic and branded rivals inching up on AstraZeneca's blockbuster respiratory drug Symbicort, the pharma giant has a game plan locked, loaded and ready to ...

Cipla petitions India to revoke Novartis respiratory drug patents, launches low-cost version of drug

Emily Wasserman Amid growing discontent from Big Pharma companies over India's patent-busting policies, generics maker Cipla is petitioning the country's government to revoke ...

A tale of ‘two worlds’ for Novartis respiratory launches in U.S. and EU

Tracy Staton Targeting different markets naturally requires using different marketing strategies. But for Novartis, which is aiming to become a major respiratory player, its approaches ...

GlaxoSmithKline cozies up to Five Prime for respiratory R&D

Damian Garde GlaxoSmithKline, facing widespread scrutiny for its underperforming respiratory business, has expanded its relationship with Five Prime Therapeutics, digging in to discover ...

Craving respiratory dominance, AstraZeneca inks $2.1B deal for Almirall’s lung meds

Tracy Staton AstraZeneca has agreed to pay $ 875 million up front–and up to $ 2.2 billion total, with milestones–for Almirall's respiratory portfolio. The deal brings ...

GlaxoSmithKline eyes rare disease to widen its respiratory lead

Damian Garde GlaxoSmithKline is looking to deepen its respiratory pipeline with another late-stage trial of the injectable mepolizumab, this time studying the drug's effects in ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS